Innovative Therapeutic Vaccine Targets HPV-Related Diseases
Researchers have developed a novel therapeutic vaccine based on recombinant protein Terah-7 that activates the immune system to combat HPV-related diseases, including cervical cancer, with promising preclinical results and plans for clinical trials.
Researchers at Imunotera Soluções Terapêuticas, a São Paulo-based startup incubated at Eretz.bio and supported by FAPESP, have developed a promising new therapeutic vaccine aimed at combatting diseases caused by human papillomavirus (HPV), including cervical cancer. This groundbreaking vaccine is based on a recombinant protein called Terah-7, which has demonstrated the ability to stimulate the immune system effectively.
The development of this vaccine involved extensive laboratory testing, including in vitro experiments with both animal and human cells, as well as in vivo studies in experimental animals. These studies revealed that the molecule can induce tumor regression, prevent disease recurrence, and impede metastasis associated with HPV.
A key finding is the molecule’s capacity to activate the immune response in human cells and regress tumors in animal models. Notably, the vaccine has shown synergistic effects when combined with standard chemotherapy treatments for cervical cancer, suggesting its potential to enhance existing therapies.
The molecule was initially discovered during the Ph.D. and postdoctoral research of the project’s lead researcher, Luana Raposo de Melo Moraes Aps, at the University of São Paulo’s Biomedical Sciences Institute. Over several years, the molecule underwent improvements to optimize its efficacy and yields. Currently, the team is preparing for clinical trials, aiming to validate its safety and effectiveness in human patients.
Imunotera plans to complete non-clinical toxicity studies by 2027, with hopes to license and transfer the technology to a multinational pharmaceutical partner for large-scale manufacturing and marketing. This innovation has the potential to significantly alter the landscape of HPV-related disease treatment on a global scale.
Participation in international events like VivaTech in Paris illustrates the company’s ambition to expand its reach and establish international partnerships. The company also envisions adapting their platform technology to other cancers, including prostate and breast cancer, as well as developing therapies for Zika, dengue, and chikungunya.
This advancement represents a substantial step forward in immunotherapy, offering hope for more effective treatments against HPV-related cancers and other viral-associated diseases.
Source: https://medicalxpress.com/news/2025-06-therapeutic-vaccine-diseases-hpv.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Research Uncovers How Gut Microbiota and Genes Worsen Ulcerative Colitis
New research reveals how interactions between gut microbiota and gene mutations, especially in OTUD3, aggravate ulcerative colitis through immune signaling pathways, opening potential for targeted therapies.
Extended Sleep and Sleep Difficulties Linked to Cognitive Issues Post-Mild Stroke
Longer sleep duration and increased time attempting to sleep are associated with brain changes and thinking problems in individuals post-mild stroke or TIA. This research highlights the importance of sleep quality in maintaining brain health.
Geroscience: A New Approach to Aging and Chronic Disease Prevention
Geroscience introduces innovative strategies to slow aging and delay chronic diseases, aiming to extend healthspan and transform healthcare for an aging population.
RFK Jr. Calls Off Critical US Health Panel Meeting Without Notice, Sparking Concerns
U.S. Health Secretary Kennedy unexpectedly canceled a key preventive health advisory panel meeting, raising concerns over political influence and the future of science-based health policy in the United States.